The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $5.60 in the prior trading day, Agilon Health Inc (NYSE: AGL) closed at $5.52, down -1.43%. In other words, the price has decreased by -$1.43 from its previous closing price. On the day, 5.05 million shares were traded. AGL stock price reached its highest trading level at $5.61 during the session, while it also had its lowest trading level at $5.31.
Ratios:
Our goal is to gain a better understanding of AGL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.36 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on May 30, 2024, initiated with a Neutral rating and assigned the stock a target price of $6.
On April 22, 2024, Citigroup started tracking the stock assigning a Neutral rating and target price of $6.
On March 06, 2024, Barclays started tracking the stock assigning a Underweight rating and target price of $5.Barclays initiated its Underweight rating on March 06, 2024, with a $5 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 29 ’23 when Schwaneke Jeffrey A. bought 22,300 shares for $11.22 per share. The transaction valued at 250,206 led to the insider holds 31,931 shares of the business.
Shaker Benjamin sold 18,750 shares of AGL for $337,455 on Sep 13 ’23. The Chief Markets Officer now owns 79,543 shares after completing the transaction at $18.00 per share. On Sep 12 ’23, another insider, Shaker Benjamin, who serves as the Chief Markets Officer of the company, sold 18,750 shares for $18.05 each. As a result, the insider received 338,481 and left with 79,543 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGL now has a Market Capitalization of 2271386112 and an Enterprise Value of 1915678208. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.42 while its Price-to-Book (P/B) ratio in mrq is 3.36. Its current Enterprise Value per Revenue stands at 0.363 whereas that against EBITDA is -8.312.
Stock Price History:
Over the past 52 weeks, AGL has reached a high of $20.37, while it has fallen to a 52-week low of $4.41. The 50-Day Moving Average of the stock is -15.28%, while the 200-Day Moving Average is calculated to be -30.11%.
Shares Statistics:
The stock has traded on average 4.49M shares per day over the past 3-months and 4630870 shares per day over the last 10 days, according to various share statistics. A total of 406.39M shares are outstanding, with a floating share count of 302.72M. Insiders hold about 26.43% of the company’s shares, while institutions hold 85.97% stake in the company. Shares short for AGL as of 1721001600 were 45858908 with a Short Ratio of 9.84, compared to 1718323200 on 43617687. Therefore, it implies a Short% of Shares Outstanding of 45858908 and a Short% of Float of 44.34.
Earnings Estimates
As of right now, 14.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.14 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$0.24 and -$0.48 for the fiscal current year, implying an average EPS of -$0.36. EPS for the following year is -$0.17, with 14.0 analysts recommending between $0.05 and -$0.31.
Revenue Estimates
18 analysts predict $1.5B in revenue for the current quarter. It ranges from a high estimate of $1.65B to a low estimate of $1.47B. As of the current estimate, Agilon Health Inc’s year-ago sales were $1.22BFor the next quarter, 18 analysts are estimating revenue of $1.46B. There is a high estimate of $1.49B for the next quarter, whereas the lowest estimate is $1.35B.
A total of 19 analysts have provided revenue estimates for AGL’s current fiscal year. The highest revenue estimate was $6.26B, while the lowest revenue estimate was $6B, resulting in an average revenue estimate of $6.07B. In the same quarter a year ago, actual revenue was $4.32BBased on 19 analysts’ estimates, the company’s revenue will be $7.41B in the next fiscal year. The high estimate is $7.97B and the low estimate is $7.03B.
